Rakuten Medical Initiates First-in-Human Phase 1 Trial of PD-L1-Targeted RM-0256 Photoimmunotherapy in Japan
General Montana
•
November 16, 2026
•
Preclinical studies suggest that RM-0256 photoimmunotherapy may target PD-L1-expressing tumor and immunosuppressive cells and inhibit PD-L1/PD-1 interaction, potentially inducing local and systemic antitumor immune responses
Source: Missoulian MT | https://missoulian.com/search/?f=rss&t=article&l=50&s=start_time&sd=desc - Read Original
Discussion (0)
Please log in to post a comment.
No comments yet. Be the first to share your thoughts!


